Aspire Private Capital’s Neuphoria Therapeutics NEUP Stock Holding History

Aspire Private Capital’s Portfolio NEUP Stock Details NEUP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17	Closed	-$88	–	681
2024 Q3	$88	Hold	17	–	–	﹤0.01%	658
2024 Q2	$153	Hold	17	–	–	﹤0.01%	659
2024 Q1	$206	Hold	17	–	–	﹤0.01%	686
2023 Q4	$296	Hold	17	–	–	﹤0.01%	661
2023 Q3	$540	Buy	+17	New	+$366	﹤0.01%	639

Other funds holding NEUP

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aspire Private Capital's NEUP Position: Q4 2024 in Review

Aspire Private Capital sold out of Neuphoria Therapeutics (NEUP) in Q4 2024, closing a stake of 17 shares — an estimated $88 sold.

Aspire Private Capital first reported a position in NEUP in Q3 2023 and held it in 5 quarters. The position peaked at $540 in Q3 2023. 8 funds tracked by Wall St. Rank hold NEUP as of Q4 2024.

Aspire Private Capital reported no remaining Neuphoria Therapeutics position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 17 Neuphoria Therapeutics shares in Q4 2024, an estimated $88.
Aspire Private Capital first reported a position in Neuphoria Therapeutics in Q3 2023 and held it in 5 quarters.
Aspire Private Capital's Neuphoria Therapeutics position peaked at $540 in Q3 2023.
8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.